Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

The interaction between splenectomy and improvement of liver function in liver cirrhosis remains unknown and so requires investigation. In summary, our results suggest that when severe PHG is ...

2009;24(9):1554-1558. To determine whether laparoscopic splenectomy improved PHG in patients with liver cirrhosis and portal hypertension, we evaluated the endoscopic findings of PHG. Among 49 ...

The findings were, as expected, those of cirrhosis of the liver ("postnecrotic" type by microscopical examination) and portal hypertension. The portal pressure was equivalent to 31 cm. of saline ...

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...

15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b ...